Table 2.
Heart disease characteristics in HFG
| Characteristics | HFG (N = 79) | p value* |
|---|---|---|
| Etiology | 0.368 | |
| Ischemic, N (%) | 41 (51.9) | |
| Chagas Disease, N (%) | 11 (13.9) | |
| Hypertensive, idiopathic and other cardiomyopathies, N (%) | 27 (34.1) | |
| NYHA | 0.392 | |
| I, N (%) | 7 (8.9) | |
| II, N (%) | 49 (62) | |
| III, N (%) | 23 (29.1) | |
| IV, N (%) | 0 | |
| MLHFQ | < 0.001 | |
| NYHA I | 16.6 ± 8 | |
| NYHA II | 30.8 ± 16.4 | |
| NYHA III | 61.5 ± 16.9 | |
| Edema | 0.406 | |
| None | 37 (59.7) | |
| 1+, N (%) | 15 (24.2) | |
| 2+, N (%) | 7 (11.3) | |
| 3+, N (%) | 3 (4.8) | |
| 4+, N (%) | 0 | |
| NT-proBNP (pg/mL) | 0.009 | |
| NYHA I | 608 ± 558.6 | |
| NYHA II | 994.05 ± 739.1 | |
| NYHA III | 3,578.6 ± 2,964.5 | |
| Systolic Blood Pressure (mmHg) | 108.9 ± 21.2 | |
| Left ventricular ejection fraction (LVEF %) | 30 ± 6.2 | |
| Basal left ventricular dimension (mm) | ||
| Men | 61.5 ± 8.3 | |
| Women | 59.9 ± 9 | |
| Estimated Pulmonary Artery Systolic Pressure (mmHg)† | 42.9 ± 10 | |
| Right ventricular enlargement, N (%) | 28 (35.4) | |
| Right ventricular systolic dysfunction, N (%) | 13 (16.5) |
HFG, Heart Failure Group; N, number; %, percentage; NYHA, New York Heart Association physical capacity classification; MLHFQ, Minnesota Living with Heart Failure Questionnaire Score; NT-proBNP = N-terminal pro B-type natriuretic peptide.
*
p value for the Kruskal-Wallis test.
†
Value estimated by the Bernoulli equation.